Search
Elapegademase
go.drugbank.com/drugs/DB14712Approved[F1937] Elapegademase is generated in _E. coli_, developed by Leadiant Biosciences and FDA approved on October 5, 2018.[L4654,F1939]
Synonyms: (CYS74>SER,ALA245>THR)ADENOSINE DEAMINASE (BOS TAURUS, BOVINE)-(1-356)-PEPTIDE, PRODUCED IN ESCHERICHIA COLI, SUBSTITUTED ON N2 OF THE N-TERMINAL ALANYL RESIDUE (A1) AND ON N6 OF LYSYL RESIDUES (K) WITH, N.ALPHA..1ALANINE AND N6 OF LYSINE RESIDUES WITHBerotralstat
go.drugbank.com/drugs/DB15982ApprovedInvestigational[A225166] Berotralstat is strictly used to prevent, but not treat, these attacks.[L26656] Developed by BioCryst Pharmaceuticals, berotralstat is marketed under the name Orladeyo as oral capsules. … [L26661] Berotralstat was approved by the European Commission on April 30, 2021 [L41965] and by Health Canada on June 06, 2022.
Synonyms: 2-[3-(aminomethyl)phenyl]-N-[5-[(R)-(3-cyanophenyl)-(cyclopropylmethylamino)methyl]-2-fluorophenyl]-5-(trifluoromethyl)pyrazole-3-carboxamide, (+)-1-(3-(aminomethyl) phenyl)-N-(5-((3-cyanophenyl)(cyclopropylmethylamino)methyl)-2-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide dihydrochlorideCasirivimab
go.drugbank.com/drugs/DB15941ApprovedInvestigationalCasirivimab and imdevimab are investigational recombinant human IgG1 monoclonal antibodies that, at this time, are not officially approved by the FDA. … [L23524] In November 2021, the same indication was approved by the EMA.
Coral snake (micrurus fulvius) immune globulin antivenin (equine)
go.drugbank.com/drugs/DB13883ApprovedNorth American Coral Snake Antivenin (Equine) is a horse-derived antivenin indicated for the treatment of envenomation caused by North American coral snake bites. … The antivenin is a refined, concentrated, and lyophilized preparation of serum globulins obtained by fractionating blood from healthy horses that have been immunized with eastern coral snake (Micrurus
Dabrafenib
go.drugbank.com/drugs/DB08912ApprovedInvestigational[L41955] In May 2018, Tafinlar (dabrafenib), in combination with Mekinist ([DB08911]), was approved to treat anaplastic thyroid cancer caused by an abnormal BRAF V600E gene.[L41955] … It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation.[L41955] It was also used for metastatic non-small cell lung cancer with the same mutation.
Rosuvastatin
go.drugbank.com/drugs/DB01098ApprovedInvestigationalelevated lipid levels by inhibiting the endogenous production of cholesterol in the liver. … [A181523] This last point results in less risk of drug-drug interactions compared to [atorvastatin], [lovastatin], and [simvastatin], which are all extensively metabolized by Cytochrome P450 (CYP) 3A4,
Products: Nb-rosuvastatin, RO-ZUTINAR ® 10 MGSulfamethoxazole
go.drugbank.com/drugs/DB01015ApprovedInvestigationalin the biosynthesis of nucleic acids and proteins which are necessary for bacterial growth and division, and using them in conjunction helps to slow the development of bacterial resistance. … [L11830] It is generally given in combination with [trimethoprim], which inhibits a sequential step in bacterial folic acid synthesis - these agents work synergistically to block two consecutive steps
Synonyms: 4-Amino-N-(5-methyl-3-isoxazolyl)benzenesulfonamideMixtures: COMAZOLE N TABLET, Nu-cotrimox Tab 400/80mgSulisobenzone
go.drugbank.com/drugs/DB11185ApprovedSulisobenzone is approved by the FDA in concentrations of up to 10% and in Canada, is approved by Health Canada at the same concentrations [F38]. … It works to filter out both UVA and UVB rays, protecting the skin from sun UV damage [L2153].
Mixtures: Givenchy Radically No Surgetics, Nioxin Scalp Treatment System 6 SPF 15 Sunscreen - Medium to Coarse HairIsopropamide
go.drugbank.com/drugs/DB01625ApprovedVet approvedWithdrawnIt is used in the treatment of peptic ulcer and other gastrointestinal disorders marked by hyperacidity and hypermotility.
Mixtures: Stelabid No 2, Stelabid No 1Pixantrone
go.drugbank.com/drugs/DB06193ApprovedWithdrawnIt is similar in structure to anthracyclines such as mitoxantrone, but exerts fewer toxic effects on cardiac tissue. [2] The lower cardio-toxic effects of pixantrone may be explained, in part, by its redox … It is currently being tested in Phase III trials. [2] Although pixantrone has not yet received FDA approval in the United States, it has been granted conditional marketing approval by the European Union